

**AMENDMENTS TO THE CLAIMS**

This listing of the claims will replace all prior versions and listings of the claims in the application.

1. **(Currently amended)** A method of treating a pulmonary infection associated with mucus or a bacterial biofilm in a patient in need thereof, comprising pulmonary administration of administering to the lungs of the patient an effective amount of a liposomal amikacin formulation, ~~liposomal/complexed antiinfective to the patient which comprises at least one a amikacin and a lipid component~~, wherein said lipid component consists essentially of a sterol and a neutral phospholipid; ~~wherein the antiinfective is an aminoglycoside, and wherein and the liposomal/complexed antiinfective has a lipid to drug ratio of less than 2.5:1.~~

2-13. **(Canceled).**

14. **(Currently amended)** The method ~~of treating~~ of claim 1, wherein the infection ~~to be treated~~ is a *Pseudomonas* ~~sp.~~, ~~staphylococcus~~, ~~streptococcus~~ *Staphylococcus sp.*, *Streptococcus sp.*, *Klebsiella sp.*, *Enterobacter sp.*, *Serratia sp.*, *Haemophilus sp.*, *Yersinia pestis*, *Burkholderia sp.*, or a *Mycobacterium sp* infection.

15. **(Currently amended)** The method ~~of treating~~ of claim 1, wherein the infection ~~to be treated~~ is a ~~pseudomonas~~ *Pseudomonas* infection.

16. **(Currently amended)** The method ~~of treating~~ of claim 1, wherein the infection ~~to be treated or ameliorated~~ is a *P. aeruginosa* infection.

17-25. **(Canceled).**

26. **(Currently amended)** The method of claim 14, wherein the infection is selected from the group consisting of a *P. aeruginosa*, *P. paucimobilis*, *P. putida*, *P. fluorescens*, *P. acidovorans*, Methicillin-resistant ~~Staphylococcus aureus~~ *Staphylococcus aureus* (MRSA), *Streptococcus pneumoniae*, *B. pseudomallei*, *B. cepacia*, *B. gladioli*, *B. multivorans*, *B. vietnamiensis*, *M. tuberculosis*, *M. avium* and *M. intracellulare*, *M. kansasii*, *M. xenopi*, *M. marinum*, *M. ulcerans*, *M. fortuitum* and *M. chelonae* infection.

27-28. **(Canceled).**

29. **(Previously presented)** The method of claim 1, wherein the patient is a cystic fibrosis patient.

30. **(Previously presented)** The method of claim 1, wherein the infection is tuberculosis.

31. **(New)** The method of claim 1, wherein the neutral phospholipid is a phosphatidylcholine.

32. **(New)** The method of claim 31, wherein the phosphatidylcholine is selected from the group consisting of egg phosphatidylcholine (EPC), soy phosphatidylcholine (SPC), hydrogenated egg phosphatidylcholine (HEPC), hydrogenated soy phosphatidylcholine (HSPC), dipalmitoyl phosphatidylcholine (DPPC), dioleoyl phosphatidylcholine (DOPC), dimyristoyl phosphatidylcholine (DMPC), palmitoylstearyl phosphatidylcholine (PSPC), and mixtures thereof.

33. **(New)** The method of claim 32, wherein the phosphatidylcholine is DPPC.

34. **(New)** The method of claim 1, wherein the sterol is cholesterol.

35. **(New)** The method of claim 1, wherein the sterol is cholesterol and the neutral phospholipid is DPPC.

36. **(New)** The method of claim 33, wherein the DPPC and cholesterol have a mole ratio of about 19:1, 9:1, 4:1, 13:7 or 1:1.

37. **(New)** The method of claim 34, wherein the DPPC and cholesterol have a mole ratio of about 1:1.

38. **(New)** The method of claim 1, wherein the administration has a dosing frequency ranging from once a day to once a week during a 14-day treatment period.

39. **(New)** The method of claim 38 wherein the administration has a dosing frequency of once a day.

40. **(New)** The method of claim 38 wherein the administration has a dosing frequency of once every two days.

41. **(New)** The method of claim 38, wherein the administration has a dosing frequency of once every three days.

42. **(New)** The method of claim 38, wherein the administration has a dosing frequency of once a week.

43. **(New)** The method of claim 1, wherein the lipid component and amikacin have a ratio of less than 2.5:1 by weight.

44. **(New)** The method of claim 43, wherein the lipid to amikacin ratio is 1.0:1 or less.

45. **(New)** The method of claim 1, wherein the amikacin is amikacin sulfate.

46. **(New)** The method of claim 45, wherein the neutral phospholipid is DPPC

47. **(New)** The method of claim 45, wherein the sterol is cholesterol.

48. **(New)** The method of claim 45, wherein the sterol is cholesterol and the neutral phospholipid is DPPC.

49. **(New)** The method of claim 48, wherein the DPPC and cholesterol have a mole ratio of about 19:1, 9:1, 4:1, 13:7 or 1:1.

50. **(New)** The method of claim 48, wherein the DPPC and cholesterol have a mole ratio of about 1.0:1.

51. **(New)** The method of claim 48, wherein the lipid component and amikacin have a ratio of less than 2.5:1 by weight.

52. **(New)** The method of claim 51, wherein the lipid component and amikacin sulfate have a ratio of less than 1.0:1 by weight.

53. **(New)** The method of claim 48, wherein the patient is a cystic fibrosis patient.